Seeking Alpha

Introgen Therapeutics, Inc. (INGN)

()

Comments on INGN

  • FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen [View article]
    This is a website for investors and traders who are interested in business news -- so why are you even here as your stupid comments... More »
    Comment by Mike Havrilla
    Jan 26 18:22 pm |
    Rating: 0 0
  • FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen [View article]
    Its a shame how you would let the fda approve your drugs cardiome pharma when you know that you are just killing people. I know the fda... More »
    Comment by natoya pearson
    Jan 26 17:14 pm |
    Rating: 0 0
  • Cancer Stocks Plunge Following ASCO Meeting [View article]
    EXCELLENT JOB,
    Comment by User 155044
    Sep 30 10:33 am |
    Rating: 0 0
  • Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile [View article]
    candeswish - i need some printer paper. can i use your stock certificates? i'll give you 0.50 per sheet. p.s. good job dr. joe.
    Comment by the biotech onion_
    Sep 2 15:12 pm |
    Rating: 0 0
  • Cancer Stocks on the Go: Winners and Losers [View article]
    I agree with paviov, However I would like to know about the new developments the phase II and III studies that are going well, where... More »
    Comment by Olboy2
    Aug 13 14:56 pm |
    Rating: 0 0
  • Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile [View article]
    I find this data difficult to interpret. It seems the success of this trial depends on the term "p53 favorable profile" given that this... More »
    Comment by Biotechy
    Aug 13 12:41 pm |
    Rating: 0 0
  • Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile [View article]
    I agree. And I see that the short interest has gone up from 9.3% a couple weeks ago to 12.08% today.
    Comment by ND-LBC
    Jun 30 13:53 pm |
    Rating: 0 0
  • Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile [View article]
    This is the author's first blog. It is obvious that this was strictly an attempt at driving down the stock. Probably just a... More »
    Comment by Jobu37
    Jun 27 09:29 am |
    Rating: 0 0
  • Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile [View article]
    I don't know about that, but his argument is built around premises and numbers that appear to be wrong. A bulletpoint at the... More »
    Comment by ND-LBC
    Jun 22 03:38 am |
    Rating: 0 0
  • Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile [View article]
    Fortunately, neither the FDA nor the physicians who will use Advexin are as dense as this author.
    Comment by candewish
    Jun 5 11:57 am |
    Rating: 0 0
  • Cancer Stocks Slide Again [View article]
    I wanted to point out an error in the article - GNVC is developing a pancreatic cancer treatment (not vaccine).
    Comment by Alan Brochstein
    Jun 18 12:54 pm |
    Rating: 0 0
  • Cancer Stocks Plunge Following ASCO Meeting [View article]
    Miles, I have a negative bias towards small biotech companies, especially ones like this that have a terrible history of underperforming... More »
    Comment by Alan Brochstein
    Jun 11 14:51 pm |
    Rating: 0 0
  • Cancer Stocks Plunge Following ASCO Meeting [View article]
    Dear Sir, What is your current opinion on Insmed? Thank you very much, Miles Roberts
    Comment by milesjroberts
    Jun 11 12:00 pm |
    Rating: 0 0
  • Cancer Stocks Soar With Annual ASCO Meeting [View article]
    Your table is too over-crowded to be useful. Next time skip the industry, HQ city and state as it is meaningless except for job seekers.... More »
    Comment by Mr Mister
    Jun 4 18:00 pm |
    Rating: 0 0
  • Cancer Stocks on the Go: Winners and Losers [View article]
    You get what you pay for, then. If I could publish this list in advance, well, I would be doing it from my boat in the Bahamas! ... More »
    Comment by Alan Brochstein
    May 30 05:14 am |
    Rating: 0 0